Healthy Living Clinic Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A medication name is not a complete evidence statement. For Healthy Living Clinic, the useful starting point is separating three things: what the company advertises, what its subscription documents commit to, and what clinical research establishes about particular treatments. Its pages provide meaningful details about compounded injectable products, professional review and monthly charges. They do not establish that the clinic’s preparations, microdosing offers or customer outcomes reproduce results from major clinical trials.

This review examines public documentation consulted October 19, 2026. The central finding is not that Healthy Living Clinic lacks a documented GLP-1 service; it clearly advertises one. Rather, several practical details remain inconsistent across its own pages. Standard tirzepatide appears at two monthly prices, geographic coverage varies by passage, and refund eligibility changes depending on which clause is read. Those discrepancies matter because evaluating a treatment service requires both clinical evidence and dependable information about the transaction.

At a glance

Documented business model: The terms describe a platform connecting users with independent licensed medical professionals who make diagnosis, treatment and prescribing decisions.
Sources: [15]
Compounded product disclosure: The homepage says its compounded formulations are not FDA-approved products or generic versions of brand-name drugs; it identifies microdosing as off-label.
Sources: [10]
Conflicting Standard price: The homepage advertises $149 monthly for non-Micro tirzepatide, while the Standard Dose product page lists $199 monthly.
Sources: [10] [8]
Recurring billing: The policy authorizes automatic renewal and says missing questionnaires, laboratory work or other requested information does not automatically pause recurring charges.
Sources: [6]
Cancellation deadline: The policy requires at least five days before the next billing date; the terms instead reference five days before the next shipment.
Sources: [6] [15]

Start with the product, not the ingredient’s reputation

Healthy Living Clinic’s homepage identifies its formulations as compounded, prepared by state-licensed U.S. pharmacies and prescribed for an individual case. It expressly says they are not FDA-approved products and are not generic versions of branded medicines. The tirzepatide product description identifies a subcutaneous injection. The concrete semaglutide listing is also injectable and says it is made in the United States by a compounding pharmacy. These descriptions establish the advertised product category, not independently verified manufacturing quality.

The FAQ also says the medical team prescribes both FDA-approved and nonapproved compounded GLP-1 medicines. However, that passage does not identify specific branded products available for purchase. Likewise, a general mention of oral semaglutide does not establish a purchasable oral option when the actual listing reviewed is injectable. Before comparing this service with another, readers need the precise prescription product, formulation and route—not simply the words semaglutide or tirzepatide.

FDA explains that compounded preparations do not undergo its premarket review for safety, effectiveness and quality. FDA recommends their use when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That recommendation is not a blanket verdict on this clinic, and nonapproval alone does not prove clinical inequivalence. Our guide to approved medicines and compounded preparations explains why approval status and clinical equivalence are separate questions.

Sources: [14] [11] [10] [12] [1]

Microdosing claims need their own evidence

Microdosing is a prominent part of Healthy Living Clinic’s offer, with a dedicated tirzepatide product and a $99 monthly advertised price. The homepage explicitly calls microdosing an off-label use and says prescriptions depend on a licensed physician determining that treatment is appropriate. That disclosure is important, but it does not supply clinical outcome data for the Micro plan. A lower-priced subscription and an ingredient associated with large trials do not, together, establish effectiveness for the advertised regimen.

STEP 1 and SURMOUNT-1 studied defined subcutaneous treatment regimens in adults with obesity or overweight plus a weight-related condition, without diabetes, over 68 and 72 weeks respectively. Neither was a study of Healthy Living Clinic or its compounded products. Their results cannot establish this provider’s outcomes, validate its microdosing offering or predict an individual result. Both trials also reported tolerability-related discontinuations and were funded by the respective drug manufacturers.

The distinction is practical rather than merely academic: ask what evidence supports the exact proposed preparation and approach, and whether the answer concerns that product or a different studied medicine. There is no basis here for ranking Healthy Living Clinic against another provider by borrowing trial percentages. Our explanation of why a clinical trial is not a telehealth performance report provides a framework for evaluating that kind of claim.

Sources: [10] [14] [3] [4]

Who provides care—and what the credentials establish

The terms describe Healthy Living Clinic as a connection platform, not the entity making diagnosis, treatment or prescribing decisions. Those decisions belong to independent licensed medical providers. The FAQ identifies a partnership with Beluga Health, P.A., described as a Florida professional corporation with an address in Houston. This division of responsibilities matters: the company taking a subscription payment, the clinician assessing a patient and the pharmacy dispensing medication are not necessarily the same organization.

The professional introductions are not fully consolidated. The FAQ names Jonah Mink, MD, as chief medical officer and claims licensure in all 50 states and Washington, D.C. The homepage instead introduces Patrick Conrad as a board-certified MD and Gregory Smith as supervising medical director. These descriptions may concern different roles, but the pages do not clearly connect them. They should be read as provider statements, not as independently checked licenses, board certifications or assignments to an individual patient.

The company also claims completion of LegitScript certification. Its corporate history dates the clinic’s launch to 2024, while the FAQ says the underlying company has operated since 2011 and is based in Colorado. Those dates describe different histories; the longer corporate history should not become a claim of 15 years delivering this GLP-1 program. As our guide to what public provider documents can prove explains, a documented assertion is not the same as external verification.

Sources: [15] [5] [12] [10]

The advertised prices are concrete, but not fully consistent

The homepage advertises tirzepatide Micro at $99 monthly and every other advertised dose at $149 monthly, including medication, doctor consultation, syringes and shipping, with no membership fee. Product pages complicate that simple presentation: Intermediate matches $149, but Standard lists $199 monthly. The crossed-out original prices below are commercial comparisons, not evidence of what customers previously paid. The Micro price block does not state when its discount ends, and the Standard discrepancy remains unresolved.

Semaglutide is listed at $149 monthly, reduced from $299. Its description specifically connects $149 with everything needed for the first month and lists medication, consultation, shipping and a syringe kit as subscription inclusions. The listing also advertises 2 mg or 4 mg presentations, but does not establish the exact vial count, volume or physical supply corresponding to each charge. A monthly billing label should not be converted into an assumed quantity or dosing schedule.

The homepage says plans are month to month, without three-, six- or twelve-month commitments or bulk prepayment to unlock a rate. However, its table says one month is due today, despite promotional language suggesting nothing is payable upfront. That does not support a free first month. Obtain the selected product’s initial charge and renewal amount in writing; the pages do not resolve insurance acceptance, HSA/FSA payment, laboratory costs or authorization assistance.

Published monthly prices and the conditions that need attention
Advertised product	Published monthly charge	Documented qualification
Compounded injectable tirzepatide Micro	$99; original price shown as $299	Microdosing is identified as off-label; no discount end date in the price block.
Compounded injectable tirzepatide Intermediate	$149; original price shown as $349	Matches the homepage’s non-Micro monthly price.
Compounded injectable tirzepatide Standard	$199; original price shown as $500	Conflicts with the homepage’s $149 non-Micro offer.
Compounded injectable semaglutide	$149; original price shown as $299	Description expressly references first-month needs and lists subscription inclusions.

Sources: [10] [14] [13] [8] [11]

Enrollment and coverage need confirmation before checkout

The homepage starts with a roughly two-minute health-history quiz requiring no card to explore fit, followed by physician review and prescribing only when appropriate. The FAQ describes a different transaction sequence: checkout, then a health questionnaire, then consultation to confirm eligibility. Another answer says the post-purchase professional may be a medical doctor or nurse practitioner. A clinician is therefore not necessarily a physician, despite the homepage’s physician-centered description.

The program advertises access for adults 18 and older with BMI of at least 25, subject to medical-history review. That is a provider-advertised threshold, not a conclusion that everyone meeting it should receive medication. The documents say the consultation considers contraindications and suitability. Readers should establish whether payment precedes review in their actual checkout flow, what information is required and which clinician or clinical organization will be responsible for the decision.

Geography is similarly unsettled. The FAQ’s specific state list omits California, Kansas, Mississippi and New Jersey, while another passage says all 50 states. It separately lists Guam, Puerto Rico and the U.S. Virgin Islands. Neither the broad claim nor the named clinician’s claimed nationwide licensure resolves those differences. Confirm both consultation availability and medication delivery for the actual destination; omission from the list is uncertainty, not proof that service is unavailable.

Sources: [10] [12]

Renewals and refunds are less simple than the sales language

Enrollment authorizes automatic recurring charges until cancellation. Importantly, the policy says billing continues even when a patient has not completed required questionnaires, laboratory work or other requested information. Delayed participation does not automatically pause or defer the subscription. That makes the clinical checklist financially consequential: establish what remains outstanding and how to stop future charges rather than assuming an uncompleted consultation or missing laboratory result prevents renewal.

The homepage advertises cancellation through the portal without a call or emailed form. The policy instead mentions customer service and requires cancellation at least five days before the next billing date; the terms count five days before the next shipment. Mid-cycle cancellation does not qualify for a prorated refund. Because shipment and billing dates need not coincide, the documents leave a meaningful operational question unresolved. Request the applicable deadline and retain a cancellation confirmation.

Refund language also conflicts. The policy promises a full refund if the medical provider finds someone unsuitable. One clause allows an attempt to stop an approved order before shipment, with a full refund if stopped in time, but excludes prescriptions already processed or in transit. Another makes the order final upon prescription approval, except where legally required. Semaglutide’s advertised 60-day “Lose weight or You Don’t Pay” guarantee lacks developed conditions here and does not resolve those boundaries.

Sources: [6] [10] [15] [11]

Pharmacy and delivery claims leave logistical gaps

The homepage says a U.S. compounding pharmacy fills prescriptions and advertises delivery in three to five business days, with syringes included. Another heading uses dispatch language, while the FAQ estimates receipt within about a week for the lower 48 states. These are not interchangeable milestones or a separately guaranteed clinical-review timeline. The consulted documentation does not specify the carrier, package tracking, refrigerated packaging or special arrangements for Alaska, Hawaii and the listed territories.

The contact page names Belmar Pharmacy at 12012 N 111th Avenue in Youngtown, Arizona, with telephone 1-800-699-8143 and fax 1-800-330-0268. Published pharmacy hours are Monday through Friday, 8 a.m.–6 p.m. Mountain Time, Saturday 9 a.m.–noon, and closed Sunday. This is a useful direct contact, but the listing does not establish Belmar as the exclusive pharmacy or identify which pharmacy would dispense a particular order.

Delivery condition deserves a separate question from delivery speed. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. FDA also reports medication-measurement and administration errors with compounded products, including some associated with hospitalization; instructions should be clarified with the prescriber or pharmacist. Our guide to reading cold-chain and delivery claims separates shipping promises from evidence about condition on arrival.

Sources: [10] [12] [9] [1]

Follow-up and privacy are part of the service evidence

Healthy Living Clinic says the medical professional remains available for follow-up questions, primarily through its portal. The FAQ also advertises community access, meal plans, workouts, coaching, customized health protocols and a monthly progress tracker. Those are specific support offerings, but they do not establish a mandatory appointment schedule, response-time guarantee or measured clinical benefit. The documentation does not clarify required laboratory testing, its cost or whether every form of follow-up is included in the subscription.

General customer contact is available at help@healthyliving.clinic and 800-599-3104, with a mailing address of 1990 Depew St. #140690, Edgewater, Colorado 80214. These channels give patients somewhere to address subscription and service questions, but the public pages do not promise a support response deadline. Clinical follow-up should also be distinguished from administrative support: NIDDK describes monitoring tolerance and response as part of treatment, not simply continuing monthly payments.

The privacy policy says HealthyLiving.Clinic is not itself a HIPAA-covered entity; independent providers or pharmacies may be covered entities, and the platform may act as a business associate in limited capacities. It also discloses advertising and retargeting tools such as Meta Pixel and automatic cookie placement. These statements do not establish a privacy violation, but they make a broad compliance slogan incomplete. Ask which entity receives clinical information and which channel is intended for sensitive medical questions.

Sources: [12] [9] [7] [2]

Questions & answers

Is Healthy Living Clinic itself FDA approved?

FDA approval applies to a specific drug product, not this platform or its pharmacy partners. Healthy Living Clinic identifies its compounded formulations as not FDA approved. Its FAQ also mentions prescribing approved medicines, but does not identify purchasable branded products in that passage. Ask for the exact product rather than treating a general GLP-1 description as an approval claim.

Sources: [10] [12] [1]

Does Standard tirzepatide cost $149 or $199 monthly?

The consulted pages do not resolve that conflict. The homepage advertises $149 monthly for non-Micro tirzepatide, while the Standard Dose listing shows $199 monthly, reduced from a displayed $500 original price. Request confirmation of the exact injectable compounded product, the first charge, included services and subsequent renewal charge before authorizing payment.

Sources: [10] [8]

Can I complete an eligibility check without paying?

The homepage offers a no-card health-history quiz, but that should not be confused with a completed prescribing consultation. The FAQ describes checkout before the questionnaire and consultation. It says a medical doctor or nurse practitioner may assess suitability after purchase. Clarify which stage is free and when the subscription begins; a quiz is not a prescription guarantee.

Sources: [10] [12]

Does canceling through the portal guarantee a refund?

No. Portal cancellation is advertised, but the written documents impose five-day advance deadlines and exclude prorated refunds for mid-cycle cancellation. They also disagree about whether an approved prescription can still be stopped and refunded before processing or shipment. Obtain written confirmation of both cancellation and any refund separately; ending future renewals does not establish reimbursement for an existing order.

Sources: [10] [6] [15]

Will Belmar Pharmacy definitely fill my prescription?

The contact page names Belmar Pharmacy and publishes its Arizona address, telephone, fax and business hours. It does not establish that every prescription goes there. Ask which pharmacy will dispense your actual order, how to contact its pharmacist and what delivery-condition process applies. The named pharmacy contact is useful documentation, not confirmation of an exclusive dispensing relationship.

Sources: [9]

What ongoing support is actually documented?

The FAQ promises follow-up questions primarily through the patient portal and lists community access, coaching, meal plans, workouts, customized protocols and monthly progress tracking. It does not establish guaranteed response times, a required clinician-visit frequency or laboratory pricing. Ask which follow-up services are included and how medical questions are escalated, rather than assuming every subscription renewal includes a substantive clinical reassessment.

Sources: [12] [2]

Our assessment

Healthy Living Clinic documents a recognizable telehealth offering: compounded injectable GLP-1 products, independent professional review, monthly subscriptions, included supplies and shipping, and portal-based follow-up. Its explicit disclosures about compounded status and off-label microdosing are useful. They do not establish product equivalence, provider-specific effectiveness or independently verified credentials. The more immediate decision barrier is documentary inconsistency: Standard pricing, geographic availability, cancellation timing and the point of nonrefundability remain unsettled. A reasonable next step is to request one written explanation covering the exact product and dispensing pharmacy, initial and recurring charges, destination eligibility, follow-up responsibilities and applicable cancellation/refund rules. Evaluate any clinical recommendation separately with the treating clinician. The public record supports describing an advertised service, but not treating every marketing promise as a settled commitment or importing trial outcomes into this clinic’s performance.

Visit Healthy Living Clinic’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Healthy Living Clinic Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the ingredient’s reputation

02Microdosing claims need their own evidence

03Who provides care—and what the credentials establish

04The advertised prices are concrete, but not fully consistent

05Enrollment and coverage need confirmation before checkout

06Renewals and refunds are less simple than the sales language

07Pharmacy and delivery claims leave logistical gaps

08Follow-up and privacy are part of the service evidence